Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: Interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

Multiple Sclerosis

Volumn 14, Issue 5, 2008, Pages 622-630

  Krakauer, Martin ^a   Sorensen, P ^a   Khademi, M ^b   Olsson, T ^b   Sellebjerg, F ^a  

^a Mental Health Services CPH   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune diseases; Cytokines; Immunotherapy; Interferon treatment; Interleukin 10; Interleukin 23; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 4; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG TARGETING; HUMAN; IN VIVO STUDY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-23; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 46849101948     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507087136     Document Type: Article

References (45)

1. Lassmann, H, Ransohoff, RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004; 25: 132-137.
2. Sospedra, M, Martin, R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
3. Murphy, KM, Reiner, SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-944.
4. Khademi, M, Illes, Z, Gielen, AW, Marta, M, Takazawa, N, Baecher-Allan, C, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004; 172: 7169-7176.
5. Becher, B, Durell, BG, Noelle, RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497.
6. Becher, B, Durell, BG, Noelle, RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003; 112: 1186-1191.
7. Cua, DJ, Sherlock, J, Chen, Y, Murphy, CA, Joyce, B, Seymour, B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
8. Hoeve, MA, Savage, ND, de Boer, T, Langenberg, DM, de Waal Malefyt, R, Ottenhoff, TH, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006; 36: 661-670.
9. Bettelli, E, Carrier, Y, Gao, W, Korn, T, Strom, TB, Oukka, M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
10. Veldhoen, M, Hocking, RJ, Atkins, CJ, Locksley, RM, Stockinger, B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189.
11. Harrington, LE, Hatton, RD, Mangan, PR, Turner, H, Murphy, TL, Murphy, KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
12. Langrish, CL, Chen, Y, Blumenschein, WM, Mattson, J, Basham, B, Sedgwick, JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
13. Park, H, Li, Z, Yang, XO, Chang, SH, Nurieva, R, Wang, YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
14. Matusevicius, D, Kivisakk, P, He, B, Kostulas, N, Ozenci, V, Fredrikson, S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-104.
15. Ishizu, T, Osoegawa, M, Mei, FJ, Kikuchi, H, Tanaka, M, Takakura, Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988-1002.
16. Li, Y, Chu, N, Hu, A, Gran, B, Rostami, A, Zhang, GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007; 130: 490-501.
17. Vaknin-Dembinsky, A, Balashov, K, Weiner, HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006; 176: 7768-7774.
18. Yong, VW, Chabot, S, Stuve, O, Williams, G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-689.
19. Hartung, HP, Bar-Or, A, Zoukos, Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251: v12-v29.
20. McRae, BL, Semnani, RT, Hayes, MP, van Seventer, GA. Type, I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 1998; 160: 4298-4304.
21. Nagai, T, Devergne, O, Mueller, TF, Perkins, DL, van Seventer, JM, van Seventer, GA. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 2003; 171: 5233-5243.
22. Rogge, L, D'Ambrosio, D, Biffi, M, Penna, G, Minetti, LJ, Presky, DH, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998; 161: 6567-6574.
23. Gayo, A, Mozo, L, Suarez, A, Tunon, A, Lahoz, C, Gutierrez, C. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS. Neurology 1999; 52: 1764-1770.
24. Khademi, M, Wallstrom, E, Andersson, M, Piehl, F, Di Marco, R, Olsson, T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000; 103: 202-210.
25. Rudick, RA, Ransohoff, RM, Lee, JC, Peppler, R, Yu, M, Mathisen, PM, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300.
26. Dayal, AS, Jensen, MA, Lledo, A, Amason, BG. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995; 45: 2173-2177.
27. Wandinger, KP, Sturzebecher, CS, Bielekova, B, Detore, G, Rosenwald, A, Staudt, LM, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-357.
28. Mirowska, D, Skierski, J, Paz, A, Koronkiewicz, M, Zaborski, J, Kruszewska, J, et al. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients. J Neurol 2003; 250: 1229-1236.
29. Del Prete, G, De Carli, M, Almerigogna, F, Giudizi, MG, Biagiotti, R, Romagnani, S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
30. Byskosh, PV, Reder, AT. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996; 1: 262-269.
31. Rudick, RA, Ransohoff, RM, Peppler, R, VanderBrug Medendorp, S, Lehmann, P, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-627.
32. Duddy, ME, Armstrong, MA, Crockard, AD, Hawkins, SA. Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis. J Neuroimmunol 1999; 101: 98-109.
33. Rep, MH, Schrijver, HM, van Lopik, T, Hintzen, RQ, Roos, MT, Ader, HJ, et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999; 96: 92-100.
34. Ersoy, E, Kus, CN, Sener, U, Coker, I, Zorlu, Y. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 2005; 12: 208-211.
35. Lunemann, JD, Aktas, O, Gniadek, P, Zschenderlein, R, Zipp, F. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients. Neurology 2001; 57: 1132-1134.
36. Waubant, E, Gee, L, Bacchetti, P, Sloan, R, Cotleur, A, Rudick, R, et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 2001; 112: 139-145.
37. Feng, X, Yau, D, Holbrook, C, Reder, AT. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002; 22: 311-319.
38. Buttmann, M, Merzyn, C, Rieckmann, P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004; 156: 195-203.
39. McDonald, WI, Compston, A, Edan, G, Goodkin, D, Hartung, HP, Lublin, FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
40. Reglier, H, Arce-Vicioso, M, Fay, M, Gougerot-Pocidalo, MA, Chollet-Martin, S. Lack of IL-10 and IL-13 production by human polymorphonuclear neutrophils. Cytokine 1998; 10: 192-198.
41. Wang, X, Chen, M, Wandinger, KP, Williams, G, Dhib-Jalbut, S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165: 548-557.
42. Furlan, R, Bergami, A, Lang, R, Brambilla, E, Franciotta, D, Martinelli, V, et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J Neuroimmunol 2000; 111: 86-92.
43. Franciotta, D, Zardini, E, Bergamaschi, R, Andreoni, L, Cosi, V. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry 2003; 74: 123-126.
44. Ferber, IA, Brocke, S, Taylor-Edwards, C, Ridgway, W, Dinisco, C, Steinman, L, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156: 5-7.
45. Gran, B, Zhang, GX, Yu, S, Li, J, Chen, XH, Ventura, ES, et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-7110.